Search

Your search keyword '"Yadav, Shalini S."' showing total 168 results
Start Over Author "Yadav, Shalini S."
168 results on '"Yadav, Shalini S."'

1. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Author

Cascone, Tina, Leung, Cheuk H., Weissferdt, Annikka, Pataer, Apar, Carter, Brett W., Godoy, Myrna C. B., Feldman, Hope, William, Jr, William N., Xi, Yuanxin, Basu, Sreyashi, Sun, Jing Jing, Yadav, Shalini S., Rojas Alvarez, Frank R., Lee, Younghee, Mishra, Aditya K., Chen, Lili, Pradhan, Monika, Guo, Haiping, Sinjab, Ansam, Zhou, Nicolas, Negrao, Marcelo V., Le, Xiuning, Gay, Carl M., Tsao, Anne S., Byers, Lauren Averett, Altan, Mehmet, Glisson, Bonnie S., Fossella, Frank V., Elamin, Yasir Y., Blumenschein, Jr, George, Zhang, Jianjun, Skoulidis, Ferdinandos, Wu, Jia, Mehran, Reza J., Rice, David C., Walsh, Garrett L., Hofstetter, Wayne L., Rajaram, Ravi, Antonoff, Mara B., Fujimoto, Junya, Solis, Luisa M., Parra, Edwin R., Haymaker, Cara, Wistuba, Ignacio I., Swisher, Stephen G., Vaporciyan, Ara A., Lin, Heather Y., Wang, Jing, Gibbons, Don L., Jack Lee, J., Ajami, Nadim J., Wargo, Jennifer A., Allison, James P., Sharma, Padmanee, Kadara, Humam, Heymach, John V., and Sepesi, Boris

Published
2023
Full Text
View/download PDF

2. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean-Nicolas, Lee, Sunyoung S, Yavuz, Betul Gok, Mohamed, Yehia I, Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S, Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching-Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C, Wolff, Robert A, Allison, James Patrick, and Sharma, Padmanee

Published
2022
Full Text
View/download PDF

3. Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma.

Author

LaPelusa, Michael Brian, primary, Chamseddine, Shadi, additional, Xiao, Lianchun, additional, Hasanov, Elshad, additional, Bhosale, Priya, additional, Abugabal, Yehia I., additional, Gok Yavuz, Betul, additional, Yadav, Shalini S., additional, Tran Cao, Hop Sanderson, additional, Xu, Li, additional, Hu, Zishuo Ian, additional, Lee, Sunyoung S., additional, Sakamuri, Divya, additional, Curran, Michael A., additional, Jindal, Sonali, additional, Duda, Gabriel Dan, additional, Sharma, Padmanee, additional, Qayyum, Aliya, additional, and Kaseb, Ahmed Omar, additional

Published
2024
Full Text
View/download PDF

4. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Author

Gao, Jianjun, Navai, Neema, Alhalabi, Omar, Siefker-Radtke, Arlene, Campbell, Matthew T., Tidwell, Rebecca Slack, Guo, Charles C., Kamat, Ashish M., Matin, Surena F., Araujo, John C., Shah, Amishi Y., Msaouel, Pavlos, Corn, Paul, Wang, Jianbo, Papadopoulos, John N., Yadav, Shalini S., Blando, Jorge M., Duan, Fei, Basu, Sreyashi, Liu, Wenbin, Shen, Yu, Zhang, Yuwei, Macaluso, Marc Daniel, Wang, Ying, Chen, Jianfeng, Zhang, Jianhua, Futreal, Andrew, Dinney, Colin, Allison, James P., Goswami, Sangeeta, and Sharma, Padmanee

Published
2020
Full Text
View/download PDF

5. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

Author

Blando, Jorge, Sharma, Anu, Higa, Maria Gisela, Zhao, Hao, Vence, Luis, Yadav, Shalini S., Kim, Jiseong, Sepulveda, Alejandro M., Sharp, Michael, Maitra, Anirban, Wargo, Jennifer, Tetzlaff, Michael, Broaddus, Russell, Katz, Matthew H. G., Varadhachary, Gauri R., Overman, Michael, Wang, Huamin, Yee, Cassian, Bernatchez, Chantale, Iacobuzio-Donahue, Christine, Basu, Sreyashi, Allison, James P., and Sharma, Padmanee

Published
2019

6. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

Author

Cascone, Tina, Weissferdt, Annikka, Godoy, Myrna C. B., William, Jr., William N., Leung, Cheuk H., Lin, Heather Y., Basu, Sreyashi, Yadav, Shalini S., Pataer, Apar, Mitchell, Kyle G., Khan, Md Abdul Wadud, Shi, Yushu, Haymaker, Cara, Solis, Luisa M., Parra, Edwin R., Kadara, Humam, Wistuba, Ignacio I., Sharma, Padmanee, Allison, James P., Ajami, Nadim J., Wargo, Jennifer A., Jenq, Robert R., Gibbons, Don L., Lee, J. Jack, Swisher, Stephen G., Vaporciyan, Ara A., Heymach, John V., and Sepesi, Boris

Published
2021
Full Text
View/download PDF

7. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

Author

Campbell, Matthew T., Matin, Surena F., Tam, Alda L., Sheth, Rahul A., Ahrar, Kamran, Tidwell, Rebecca S., Rao, Priya, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Jonasch, Eric, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Y., Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Chen, Hong, Espejo, Alexsandra B., Allison, James P., Yadav, Shalini S., and Sharma, Padmanee

Published
2021
Full Text
View/download PDF

8. Inflammation and Prostate Cancer

Author

Tewari, Ashutosh K., Stockert, Jennifer A., Yadav, Shalini S., Yadav, Kamlesh K., Khan, Irtaza, COHEN, IRUN R., Series Editor, LAJTHA, ABEL, Series Editor, LAMBRIS, JOHN D., Series Editor, PAOLETTI, RODOLFO, Series Editor, REZAEI, NIMA, Series Editor, and Schatten, Heide, editor

Published
2018
Full Text
View/download PDF

9. Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis

Author

Siddiqui, Bilal A, primary, Palaskas, Nicolas L, additional, Basu, Sreyashi, additional, Dai, Yibo, additional, He, Zhong, additional, Yadav, Shalini S, additional, Allison, James, additional, Sheth, Rahul, additional, Tummala, Sudhakar, additional, Buja, L Maximilian, additional, Bhattacharjee, Meenakshi, additional, Iliescu, Cezar A, additional, Rawther-Karedath, Anishia, additional, Deswal, Anita, additional, Wang, Linghua, additional, Sharma, Padmanee, additional, and Subudhi, Sumit K, additional

Published
2023
Full Text
View/download PDF

10. Supplementary Table from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Author

Ferrarotto, Renata, primary, Amit, Moran, primary, Nagarajan, Priyadharsini, primary, Rubin, M. Laura, primary, Yuan, Ying, primary, Bell, Diana, primary, El-Naggar, Adel K., primary, Johnson, Jason M., primary, Morrison, William H., primary, Rosenthal, David I., primary, Glisson, Bonnie S., primary, Johnson, Faye M., primary, Lu, Charles, primary, Mott, Frank E., primary, Esmaeli, Bita, primary, Diaz, Eduardo M., primary, Gidley, Paul W., primary, Goepfert, Ryan P., primary, Lewis, Carol M., primary, Weber, Randal S., primary, Wargo, Jennifer A., primary, Basu, Sreyashi, primary, Duan, Fei, primary, Yadav, Shalini S., primary, Sharma, Padmanee, primary, Allison, James P., primary, Myers, Jeffrey N., primary, and Gross, Neil D., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table S3 from Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer

Author

Alexander, Joan, primary, Kendall, Jude, primary, McIndoo, Jean, primary, Rodgers, Linda, primary, Aboukhalil, Robert, primary, Levy, Dan, primary, Stepansky, Asya, primary, Sun, Guoli, primary, Chobardjiev, Lubomir, primary, Riggs, Michael, primary, Cox, Hilary, primary, Hakker, Inessa, primary, Nowak, Dawid G., primary, Laze, Juliana, primary, Llukani, Elton, primary, Srivastava, Abhishek, primary, Gruschow, Siobhan, primary, Yadav, Shalini S., primary, Robinson, Brian, primary, Atwal, Gurinder, primary, Trotman, Lloyd C., primary, Lepor, Herbert, primary, Hicks, James, primary, Wigler, Michael, primary, and Krasnitz, Alexander, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Author

Ferrarotto, Renata, primary, Amit, Moran, primary, Nagarajan, Priyadharsini, primary, Rubin, M. Laura, primary, Yuan, Ying, primary, Bell, Diana, primary, El-Naggar, Adel K., primary, Johnson, Jason M., primary, Morrison, William H., primary, Rosenthal, David I., primary, Glisson, Bonnie S., primary, Johnson, Faye M., primary, Lu, Charles, primary, Mott, Frank E., primary, Esmaeli, Bita, primary, Diaz, Eduardo M., primary, Gidley, Paul W., primary, Goepfert, Ryan P., primary, Lewis, Carol M., primary, Weber, Randal S., primary, Wargo, Jennifer A., primary, Basu, Sreyashi, primary, Duan, Fei, primary, Yadav, Shalini S., primary, Sharma, Padmanee, primary, Allison, James P., primary, Myers, Jeffrey N., primary, and Gross, Neil D., primary

Published
2023
Full Text
View/download PDF

13. Supplementary case reports from Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer

Author

Alexander, Joan, primary, Kendall, Jude, primary, McIndoo, Jean, primary, Rodgers, Linda, primary, Aboukhalil, Robert, primary, Levy, Dan, primary, Stepansky, Asya, primary, Sun, Guoli, primary, Chobardjiev, Lubomir, primary, Riggs, Michael, primary, Cox, Hilary, primary, Hakker, Inessa, primary, Nowak, Dawid G., primary, Laze, Juliana, primary, Llukani, Elton, primary, Srivastava, Abhishek, primary, Gruschow, Siobhan, primary, Yadav, Shalini S., primary, Robinson, Brian, primary, Atwal, Gurinder, primary, Trotman, Lloyd C., primary, Lepor, Herbert, primary, Hicks, James, primary, Wigler, Michael, primary, and Krasnitz, Alexander, primary

Published
2023
Full Text
View/download PDF

14. Data from Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer

Author

Alexander, Joan, primary, Kendall, Jude, primary, McIndoo, Jean, primary, Rodgers, Linda, primary, Aboukhalil, Robert, primary, Levy, Dan, primary, Stepansky, Asya, primary, Sun, Guoli, primary, Chobardjiev, Lubomir, primary, Riggs, Michael, primary, Cox, Hilary, primary, Hakker, Inessa, primary, Nowak, Dawid G., primary, Laze, Juliana, primary, Llukani, Elton, primary, Srivastava, Abhishek, primary, Gruschow, Siobhan, primary, Yadav, Shalini S., primary, Robinson, Brian, primary, Atwal, Gurinder, primary, Trotman, Lloyd C., primary, Lepor, Herbert, primary, Hicks, James, primary, Wigler, Michael, primary, and Krasnitz, Alexander, primary

Published
2023
Full Text
View/download PDF

15. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Author

Siddiqui, Bilal A, primary, Chapin, Brian F, additional, Jindal, Sonali, additional, Duan, Fei, additional, Basu, Sreyashi, additional, Yadav, Shalini S, additional, Gu, Ai-Di, additional, Espejo, Alexsandra B, additional, Kinder, Michelle, additional, Pettaway, Curtis A, additional, Ward, John F, additional, Tidwell, Rebecca S S, additional, Troncoso, Patricia, additional, Corn, Paul G, additional, Logothetis, Christopher J, additional, Knoblauch, Roland, additional, Hutnick, Natalie, additional, Gottardis, Marco, additional, Drake, Charles G, additional, Sharma, Padmanee, additional, and Subudhi, Sumit K, additional

Published
2023
Full Text
View/download PDF

16. Epigenetic–Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer

Author

Das, Chandrima, primary, Adhikari, Swagata, additional, Bhattacharya, Apoorva, additional, Chakraborty, Sanjukta, additional, Mondal, Payel, additional, Yadav, Shalini S., additional, Adhikary, Santanu, additional, Hunt, Clayton R., additional, Yadav, Kamlesh K., additional, Pandita, Shruti, additional, Roy, Siddhartha, additional, Tainer, John A., additional, Ahmed, Zamal, additional, and Pandita, Tej K., additional

Published
2023
Full Text
View/download PDF

17. Breakthroughs and Applications of Organ-on-a-Chip Technology

Author

Koyilot, Mufeeda C., primary, Natarajan, Priyadarshini, additional, Hunt, Clayton R., additional, Sivarajkumar, Sonish, additional, Roy, Romy, additional, Joglekar, Shreeram, additional, Pandita, Shruti, additional, Tong, Carl W., additional, Marakkar, Shamsudheen, additional, Subramanian, Lakshminarayanan, additional, Yadav, Shalini S., additional, Cherian, Anoop V., additional, Pandita, Tej K., additional, Shameer, Khader, additional, and Yadav, Kamlesh K., additional

Published
2022
Full Text
View/download PDF

18. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, Sharma, Padmanee, Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, and Sharma, Padmanee

Abstract

Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma. Methods: In this single-centre, randomised, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma were randomly assigned (1:1) to receive 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery at 6 weeks) followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for 2 years, or 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery) plus one dose of 1 mg/kg of ipilimumab intravenously concurrently with the first preoperative dose of nivolumab, followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for up to 2 years plus 1 mg/kg of ipilimumab intravenously every 6 weeks for up to four cycles. Patients were randomly assigned to the treatment groups by use of block randomisation with a random block size. The primary endpoint was the safety and tolerability of nivolumab with or without ipilimumab. Secondary endpoints were the proportion of patients with an overall response, time to progression, and progression-free survival. This trial is registered with ClinicalTrials.gov (NCT03222076) and is completed. Findings: Between Oct 30, 2017, and Dec 3, 2019, 30 patients were enrolled and 27 were randomly assigned: 13 to nivolumab and 14 to nivolumab plus ipilimumab. Grade 3–4 adverse events were higher with nivolumab plus ipilimumab (six [43%] of 14 patients) than with nivolumab alone (three [23%] of 13). The most common treatment-related adverse events of any grade were increased alanine aminotransferase (three [23%] of 13 patients on nivolumab vs seven [50%] of 14 pa

Published
2022

19. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy

Author

Msaouel, Pavlos, primary, Goswami, Sangeeta, additional, Thall, Peter F., additional, Wang, Xuemei, additional, Yuan, Ying, additional, Jonasch, Eric, additional, Gao, Jianjun, additional, Campbell, Matthew T., additional, Shah, Amishi Yogesh, additional, Corn, Paul Gettys, additional, Tam, Alda L., additional, Ahrar, Kamran, additional, Rao, Priya, additional, Sircar, Kanishka, additional, Cohen, Lorenzo, additional, Basu, Sreyashi, additional, Duan, Fei, additional, Jindal, Sonali, additional, Zhang, Yuwei, additional, Chen, Hong, additional, Yadav, Shalini S., additional, Shazer, Ronald, additional, Der-Torossian, Hirak, additional, Allison, James P., additional, Sharma, Padmanee, additional, and Tannir, Nizar M., additional

Published
2022
Full Text
View/download PDF

20. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Author

Ferrarotto, Renata, primary, Amit, Moran, additional, Nagarajan, Priyadharsini, additional, Rubin, M. Laura, additional, Yuan, Ying, additional, Bell, Diana, additional, El-Naggar, Adel K., additional, Johnson, Jason M., additional, Morrison, William H., additional, Rosenthal, David I., additional, Glisson, Bonnie S., additional, Johnson, Faye M., additional, Lu, Charles, additional, Mott, Frank E., additional, Esmaeli, Bita, additional, Diaz, Eduardo M., additional, Gidley, Paul W., additional, Goepfert, Ryan P., additional, Lewis, Carol M., additional, Weber, Randal S., additional, Wargo, Jennifer A., additional, Basu, Sreyashi, additional, Duan, Fei, additional, Yadav, Shalini S., additional, Sharma, Padmanee, additional, Allison, James P., additional, Myers, Jeffrey N., additional, and Gross, Neil D., additional

Published
2022
Full Text
View/download PDF

24. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Author

Subudhi, Sumit K, primary, Siddiqui, Bilal A, additional, Aparicio, Ana M, additional, Yadav, Shalini S, additional, Basu, Sreyashi, additional, Chen, Hong, additional, Jindal, Sonali, additional, Tidwell, Rebecca S S, additional, Varma, Ashwin, additional, Logothetis, Christopher J, additional, Allison, James P, additional, Corn, Paul G, additional, and Sharma, Padmanee, additional

Published
2021
Full Text
View/download PDF

25. MX2 is an interferon-induced inhibitor of HIV-1 infection

Author

Kane, Melissa, Yadav, Shalini S., Bitzegeio, Julia, Kutluay, Sebla B., Zang, Trinity, Wilson, Sam J., Schoggins, John W., Rice, Charles M., Yamashita, Masahiro, Hatziioannou, Theodora, and Bieniasz, Paul D.

Subjects
Interferon -- Physiological aspects -- Health aspects, Host-parasite relationships -- Research, HIV infection -- Physiological aspects -- Genetic aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

HIV-1 replication can be inhibited by type I interferon (IFN), and the expression of a number of gene products with anti-HIV-1 activity is induced by type I IFN (1,2). However, none of the known antiretroviral proteins can account for the ability of type I IFN to inhibit early, preintegration phases of the HIV-1 replication cycle in human cells (3,4). Here, by comparing gene expression profiles in cell lines that differ in their ability to support the inhibitory action of IFN-α at early steps of the HIV-1 replication cycle, we identify myxovirus resistance 2 (MX2) as an interferon-induced inhibitor of HIV-1 infection. Expression of MX2 reduces permissiveness to a variety of lentiviruses, whereas depletion of MX2 using RNA interference reduces the anti-HIV-1 potency of IFN-α. HIV-1 reverse transcription proceeds normally in MX2-expressing cells, but 2-long terminal repeat circular forms of HIV-1 DNA are less abundant, suggesting that MX2 inhibits HIV-1 nuclear import, or destabilizes nuclear HIV-1 DNA. Consistent with this notion, mutations in the HIV-1 capsid protein that are known, or suspected, to alter the nuclear import pathways used by HIV-1 confer resistance to MX2, whereas preventing cell division increases MX2 potency. Overall, these findings indicate that MX2 is an effector of the anti-HIV-1 activity of type-I IFN, and suggest that MX2 inhibits HIV-1 infection by inhibiting capsid-dependent nuclear import of subviral complexes., We and others have previously identified proteins with antiretroviral activity on the basis of their differential expression in cells that are permissive or non-permissive with respect to particular steps in [...]

Published
2013
Full Text
View/download PDF

26. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Author

Ferrarotto, Renata, primary, Amit, Moran, additional, Nagarajan, Priyadharsini, additional, Rubin, M. Laura, additional, Yuan, Ying, additional, Bell, Diana, additional, El-Naggar, Adel K., additional, Johnson, Jason M., additional, Morrison, William H., additional, Rosenthal, David I., additional, Glisson, Bonnie S., additional, Johnson, Faye M., additional, Lu, Charles, additional, Mott, Frank E., additional, Esmaeli, Bita, additional, Diaz, Eduardo M., additional, Gidley, Paul W., additional, Goepfert, Ryan P., additional, Lewis, Carol M., additional, Weber, Randal S., additional, Wargo, Jennifer A., additional, Basu, Sreyashi, additional, Duan, Fei, additional, Yadav, Shalini S., additional, Sharma, Padmanee, additional, Allison, James P., additional, Myers, Jeffrey N., additional, and Gross, Neil D., additional

Published
2021
Full Text
View/download PDF

28. The Next Decade of Immune Checkpoint Therapy

Author

Sharma, Padmanee, primary, Siddiqui, Bilal A., additional, Anandhan, Swetha, additional, Yadav, Shalini S., additional, Subudhi, Sumit K., additional, Gao, Jianjun, additional, Goswami, Sangeeta, additional, and Allison, James P., additional

Published
2021
Full Text
View/download PDF

30. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Author

Chang, Kwang-Yu, primary, Chiang, Nai-Jung, additional, Wu, Shang-Yin, additional, Yen, Chia-Jui, additional, Chen, Shang-Hung, additional, Yeh, Yu-Min, additional, Li, Chien-Feng, additional, Feng, Xiaoxing, additional, Wu, Katherine, additional, Johnston, Amanda, additional, Bomalaski, John S., additional, Wu, Bor-Wen, additional, Gao, Jianjun, additional, Subudhi, Sumit K., additional, Kaseb, Ahmed O., additional, Blando, Jorge M., additional, Yadav, Shalini S., additional, Szlosarek, Peter W., additional, and Chen, Li-Tzong, additional

Published
2021
Full Text
View/download PDF

31. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

Author

Subudhi, Sumit K., primary, Vence, Luis, additional, Zhao, Hao, additional, Blando, Jorge, additional, Yadav, Shalini S., additional, Xiong, Qing, additional, Reuben, Alexandre, additional, Aparicio, Ana, additional, Corn, Paul G., additional, Chapin, Brian F., additional, Pisters, Louis L., additional, Troncoso, Patricia, additional, Tidwell, Rebecca Slack, additional, Thall, Peter, additional, Wu, Chang-Jiun, additional, Zhang, Jianhua, additional, Logothetis, Christopher L., additional, Futreal, Andrew, additional, Allison, James P., additional, and Sharma, Padmanee, additional

Published
2020
Full Text
View/download PDF

33. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

Author

de Groot, John, primary, Penas-Prado, Marta, primary, Alfaro-Munoz, Kristin, primary, Hunter, Kathy, primary, Pei, Be Lian, primary, O’Brien, Barbara, primary, Weathers, Shiao-Pei, primary, Loghin, Monica, primary, Kamiya Matsouka, Carlos, primary, Yung, W K Alfred, primary, Mandel, Jacob, primary, Wu, Jimin, primary, Yuan, Ying, primary, Zhou, Shouhao, primary, Fuller, Gregory N, primary, Huse, Jason, primary, Rao, Ganesh, primary, Weinberg, Jeffrey S, primary, Prabhu, Sujit S, primary, McCutcheon, Ian E, primary, Lang, Frederick F, primary, Ferguson, Sherise D, primary, Sawaya, Raymond, primary, Colen, Rivka, primary, Yadav, Shalini S, primary, Blando, Jorge, primary, Vence, Luis, primary, Allison, James, primary, Sharma, Padmanee, primary, and Heimberger, Amy B, primary

Published
2019
Full Text
View/download PDF

34. Characterization and Comparison of GITR Expression in Solid Tumors

Author

Vence, Luis, primary, Bucktrout, Samantha L., additional, Fernandez Curbelo, Irina, additional, Blando, Jorge, additional, Smith, Bevin M., additional, Mahne, Ashley E., additional, Lin, John C., additional, Park, Terrence, additional, Pascua, Edward, additional, Sai, Tao, additional, Chaparro-Riggers, Javier, additional, Subudhi, Sumit K., additional, Scutti, Jorge B., additional, Higa, Maria G., additional, Zhao, Hao, additional, Yadav, Shalini S., additional, Maitra, Anirban, additional, Wistuba, Ignacio I., additional, Allison, James P., additional, and Sharma, Padmanee, additional

Published
2019
Full Text
View/download PDF

37. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.

Author

Kwang-Yu Chang, Nai-Jung Chiang, Shang-Yin Wu, Chia-Jui Yen, Shang-Hung Chen, Yu-Min Yeh, Chien-Feng Li, Xiaoxing Feng, Wu, Katherine, Johnston, Amanda, Bomalaski, John S., Bor-Wen Wu, Jianjun Gao, Subudhi, Sumit K., Kaseb, Ahmed O., Blando, Jorge M., Yadav, Shalini S., Szlosarek, Peter W., and Li-Tzong Chen

Subjects
ARGININE deiminase, T cells, PROGRAMMED death-ligand 1, PEMBROLIZUMAB, PROGRAMMED cell death 1 receptors
Abstract

Background: Pegylated arginine deiminase (ADI-PEG 20) is a metabolism-based strategy that depletes arginine, resulting in tumoral stress and cytotoxicity. Preclinically, ADI-PEG 20 modulates T-cell activity and enhances the therapeutic efficacy of programmed death-1 (PD-1) inhibition. Methods: A phase 1b study, including a dose-escalation cohort and an expansion cohort, was undertaken to explore the effects of ADI-PEG 20 in combination with pembrolizumab, an anti-PD-1 antibody, for safety, pharmacodynamics, and response. CD3 levels and programmed death-ligand 1 (PD-L1) expression were assessed in paired biopsies collected prior to and after ADI-PEG 20 treatment but before pembrolizumab. Results: Twenty-five patients, nine in the dose-escalation cohort and sixteen in the expansion cohort, were recruited. Treatment was feasible with adverse events consistent with those known for each agent, except for Grade 3/4 neutropenia which was higher than expected, occurring in 10/25 (40%) patients. Mean arginine levels were suppressed for 1-3 weeks, but increased gradually. CD3+ T cells increased in 10/12 (83.3%) subjects following ADI-PEG 20 treatment, including in three partial responders (p = .02). PD-L1 expression was low and increased in 3/10 (30%) of subjects. Partial responses occurred in 6/25 (24%) heavily pretreated patients, in both argininosuccinate synthetase 1 proficient and deficient subjects. Conclusions: The immunometabolic combination was safe with the caveat that the incidence of neutropenia might be increased compared with either agent alone. ADI-PEG 20 treatment increased T cell infiltration in the low PD-L1 tumor microenvironment. The recommended phase 2 doses are 36 mg/m² weekly for ADI-PEG 20 and 200 mg every 3 weeks for pembrolizumab. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. The Use of Biomarkers in Prostate Cancer Screening and Treatment

Author

Alford, Ashley V., Brito, Joseph M., Yadav, Kamlesh K., Yadav, Shalini S., Tewari, Ashutosh K., and Renzulli, Joseph

Subjects
Treatment Update
Abstract

Prostate cancer screening and diagnosis has been guided by prostate-specific antigen levels for the past 25 years, but with the most recent US Preventive Services Task Force screening recommendations, as well as concerns regarding overdiagnosis and overtreatment, a new wave of prostate cancer biomarkers has recently emerged. These assays allow the testing of urine, serum, or prostate tissue for molecular signs of prostate cancer, and provide information regarding both diagnosis and prognosis. In this review, we discuss 12 commercially available biomarker assays approved for the diagnosis and treatment of prostate cancer. The results of clinical validation studies and clinical decision-making studies are presented. This information is designed to assist urologists in making clinical decisions with respect to ordering and interpreting these tests for different patients. There are numerous fluid and biopsy-based genomic tests available for prostate cancer patients that provide the physician and patient with different information about risk of future disease and treatment outcomes. It is important that providers be able to recommend the appropriate test for each individual patient; this decision is based on tissue availability and prognostic information desired. Future studies will continue to emphasize the important role of genomic biomarkers in making individualized treatment decisions for prostate cancer patients.

Published
2017

39. Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

Author

Khouri, Issa F., primary, Borin Scutti, Jorge A, additional, Milton, Denái R., additional, Nicholas, Courtney, additional, Pineda, Mariana, additional, Jabbour, Elias J., additional, Bassett, Roland L., additional, Yadav, Shalini S, additional, Vence, Luis M, additional, Allison, James P, additional, Gulbis, Alison, additional, and Sharma, Padmanee, additional

Published
2018
Full Text
View/download PDF

42. Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer

Author

Alexander, Joan, primary, Kendall, Jude, additional, McIndoo, Jean, additional, Rodgers, Linda, additional, Aboukhalil, Robert, additional, Levy, Dan, additional, Stepansky, Asya, additional, Sun, Guoli, additional, Chobardjiev, Lubomir, additional, Riggs, Michael, additional, Cox, Hilary, additional, Hakker, Inessa, additional, Nowak, Dawid G., additional, Laze, Juliana, additional, Llukani, Elton, additional, Srivastava, Abhishek, additional, Gruschow, Siobhan, additional, Yadav, Shalini S., additional, Robinson, Brian, additional, Atwal, Gurinder, additional, Trotman, Lloyd C., additional, Lepor, Herbert, additional, Hicks, James, additional, Wigler, Michael, additional, and Krasnitz, Alexander, additional

Published
2018
Full Text
View/download PDF

43. Window-of-Opportunity Clinical Trial of Pembrolizumab in Recurrent Glioblastoma (GBM) Patients

Author

de Groot, John, primary, Penas-Prado, Marta, additional, Alfaro-Munoz, Kristin D., additional, Hunter, Kathy, additional, O’Brien, Barbara, additional, Weathers, Shiao-Pei, additional, Loghin, Monica, additional, Matsouka, Carlos Kamiya, additional, Yung, W. K. Alfred, additional, Mandel, Jacob, additional, Zhou, Shouhao, additional, Fuller, Gregory N., additional, Huse, Jason, additional, Rao, Ganesh, additional, Weinberg, Jeffrey S., additional, Prabhu, Sujit S., additional, McCutcheon, Ian E., additional, Lang, Frederick F., additional, Ferguson, Sherise, additional, Sawaya, Raymond, additional, Colen, Rivka, additional, Yadav, Shalini S., additional, Blando, Jorge, additional, Yuan, Ying, additional, Vence, Luis, additional, Allison, James, additional, Sharma, Padmanee, additional, and Heimberger, Amy, additional

Published
2018
Full Text
View/download PDF

44. The Molecular Taxonomy of Primary Prostate Cancer

Author

Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Broad Institute of MIT and Harvard, Massachusetts Institute of Technology. Department of Biology, Bradley, Robert K, Carmell, Michelle, Carter, Scott, Chin, Lynda, Cibulskis, Kristian, Getz, Gad Asher, Heiman, David, Lander, Eric Steven, Lin, Pei, Loda, Massimo, Meyerson, Matthew L, Park, Peter J, Seidman, Jonathan, Sougnez, Carrie L, Verhaak, Roel, Voet, Douglas, Abeshouse, Adam, Ahn, Jaeil, Akbani, Rehan, Ally, Adrian, Amin, Samirkumar, Andry, Christopher D., Annala, Matti, Aprikian, Armen, Armenia, Joshua, Arora, Arshi, Auman, J. Todd, Balasundaram, Miruna, Balu, Saianand, Barbieri, Christopher E., Bauer, Thomas, Benz, Christopher C., Bergeron, Alain, Beroukhim, Rameen, Berrios, Mario, Bivol, Adrian, Bodenheimer, Tom, Boice, Lori, Bootwalla, Moiz S., dos Reis, Rodolfo Borges, Boutros, Paul C., Bowen, Jay, Bowlby, Reanne, Boyd, Jeffrey, Breggia, Anne, Brimo, Fadi, Brooks, Denise, Broom, Bradley M., Bryce, Alan H., Bubley, Glenn, Burks, Eric, Butterfield, Yaron S.N., Button, Michael, Canes, David, Carlotti, Carlos G., Carlsen, Rebecca, Carroll, Peter R., Cartun, Richard, Carver, Brett S., Chan, June M., Chang, Matthew T., Chen, Yu, Costello, Anthony J., Cherniack, Andrew D., Chevalier, Simone, Cho, Juok, Chu, Andy, Chuah, Eric, Chudamani, Sudha, Ciriello, Giovanni, Clarke, Amanda, Cooperberg, Matthew R., Corcoran, Niall M., Cowan, Janet, Crain, Daniel, Curley, Erin, David, Kerstin, Demchok, John A., Demichelis, Francesca, Dhalla, Noreen, Dhir, Rajiv, Doueik, Alexandre, Drake, Bettina, Dvinge, Heidi, Dyakova, Natalya, Felau, Ina, Ferguson, Martin L., Frazer, Scott, Freedland, Stephen, Fu, Yao, Bristow, Christopher A., Gao, Jianjiong, Gardner, Johanna, Gastier-Foster, Julie M., Gehlenborg, Nils, Gerken, Mark, Gerstein, Mark B., Godwin, Andrew K., Gopalan, Anuradha, Graefen, Markus, Graim, Kiley, Gribbin, Thomas, Guin, Ranabir, Gupta, Manaswi, Hadjipanayis, Angela, Haider, Syed, Hamel, Lucie, Hayes, D. Neil, Hess, Julian, Hoadley, Katherine A., Holbrook, Andrea H., Holt, Robert A., Holway, Antonia, Hovens, Christopher M., Hoyle, Alan P., Huang, Mei, Hutter, Carolyn M., Ittmann, Michael, Iype, Lisa, Jefferys, Stuart R., Jones, Corbin D., Jones, Steven J.M., Juhl, Hartmut, Kahles, Andre, Kane, Christopher J., Kasaian, Katayoon, Kerger, Michael, Khurana, Ekta, Kim, Jaegil, Klein, Robert J., Kucherlapati, Raju, Lacombe, Louis, Ladanyi, Marc, Lai, Phillip H., Laird, Peter W., Latour, Mathieu, Lawrence, Michael S., Lau, Kevin, LeBien, Tucker, Lee, Darlene, Lee, Semin, Lehmann, Kjong-Van, Leraas, Kristen M., Leshchiner, Ignaty, Leung, Robert, Libertino, John A., Lichtenberg, Tara M., Linehan, W. Marston, Ling, Shiyun, Lippman, Scott M., Liu, Jia, Liu, Wenbin, Lochovsky, Lucas, Logothetis, Christopher, Lolla, Laxmi, Longacre, Teri, Lu, Yiling, Luo, Jianhua, Ma, Yussanne, Mahadeshwar, Harshad S., Mallery, David, Mariamidze, Armaz, Marra, Marco A., Mayo, Michael, McCall, Shannon, McKercher, Ginette, Meng, Shaowu, Mes-Masson, Anne-Marie, Merino, Maria J., Mieczkowski, Piotr A., Mills, Gordon B., Mills Shaw, Kenna R., Minner, Sarah, Moinzadeh, Alireza, Moore, Richard A., Morris, Scott, Morrison, Carl, Mose, Lisle E., Mungall, Andrew J., Murray, Bradley A., Myers, Jerome B., Naresh, Rashi, Nelson, Joel, Nelson, Mark A., Nelson, Peter S., Newton, Yulia, Noble, Michael S., Noushmehr, Houtan, Nykter, Matti, Pantazi, Angeliki, Parfenov, Michael, Parker, Joel S., Paulauskis, Joseph, Penny, Robert, Perou, Charles M., Piche, Alain, Pihl, Todd, Pinto, Peter A., Prandi, Davide, Protopopov, Alexei, Ramirez, Nilsa C., Rao, Arvind, Rathmell, W. Kimryn, Ratsch, Gunnar, Ren, Xiaojia, Reuter, Victor E., Reynolds, Sheila M., Rhie, Suhn K., Rieger-Christ, Kimberly, Roach, Jeffrey, Robertson, A. Gordon, Robinson, Brian, Rubin, Mark A., Saad, Fred, Sadeghi, Sara, Saksena, Gordon, Saller, Charles, Salner, Andrew, Sanchez-Vega, Francisco, Sander, Chris, Sandusky, George, Sauter, Guido, Sboner, Andrea, Scardino, Peter T., Scarlata, Eleonora, Schein, Jacqueline E., Schlomm, Thorsten, Schmidt, Laura S., Schultz, Nikolaus, Schumacher, Steven E., Neder, Luciano, Seth, Sahil, Sharp, Alexis, Shelton, Candace, Shelton, Troy, Shen, Hui, Shen, Ronglai, Sherman, Mark, Sheth, Margi, Shi, Yan, Shih, Juliann, Shmulevich, Ilya, Simko, Jeffry, Simon, Ronald, Simons, Janae V., Sipahimalani, Payal, Skelly, Tara, Sofia, Heidi J., Soloway, Matthew G., Song, Xingzhi, Sorcini, Andrea, Stepa, Serghei, Stewart, Chip, Stewart, John, Stuart, Joshua M., Sullivan, Travis B., Sun, Charlie, Sun, Huandong, Tam, Angela, Tan, Donghui, Tang, Jiabin, Tarnuzzer, Roy, Tarvin, Katherine, Taylor, Barry S., Teebagy, Patrick, Tenggara, Imelda, Tetu, Bernard, Tewari, Ashutosh, Thiessen, Nina, Thompson, Timothy, Thorne, Leigh B., Tirapelli, Daniela P., Tomlins, Scott A., Trevisan, Felipe Amstalden, Troncoso, Patricia, True, Lawrence D., Tsourlakis, Maria Christina, Tyekucheva, Svitlana, Van Allen, Eliezer, Van Den Berg, David J., Veluvolu, Umadevi, Vocke, Cathy D., Wan, Yunhu, Wang, Qingguo, Wang, Wenyi, Wang, Zhining, Weinhold, Nils, Weinstein, John N., Weisenberger, Daniel J., Wilkerson, Matthew D., Wise, Lisa, Witte, John, Wu, Chia-Chin, Wu, Junyuan, Wu, Ye, Xu, Andrew W., Yadav, Shalini S., Yang, Liming, Yang, Lixing, Yau, Christina, Ye, Huihui, Yena, Peggy, Zeng, Thomas, Zenklusen, Jean C., Zhang, Hailei, Zhang, Jiashan, Zhang, Wei, Zhong, Yi, Zhu, Kelsey, Zmuda, Erik, Cancer Genome Atlas Research Network, Bradley, Robert K., Meyerson, Matthew L., Park, Peter J., Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Broad Institute of MIT and Harvard, Massachusetts Institute of Technology. Department of Biology, Bradley, Robert K, Carmell, Michelle, Carter, Scott, Chin, Lynda, Cibulskis, Kristian, Getz, Gad Asher, Heiman, David, Lander, Eric Steven, Lin, Pei, Loda, Massimo, Meyerson, Matthew L, Park, Peter J, Seidman, Jonathan, Sougnez, Carrie L, Verhaak, Roel, Voet, Douglas, Abeshouse, Adam, Ahn, Jaeil, Akbani, Rehan, Ally, Adrian, Amin, Samirkumar, Andry, Christopher D., Annala, Matti, Aprikian, Armen, Armenia, Joshua, Arora, Arshi, Auman, J. Todd, Balasundaram, Miruna, Balu, Saianand, Barbieri, Christopher E., Bauer, Thomas, Benz, Christopher C., Bergeron, Alain, Beroukhim, Rameen, Berrios, Mario, Bivol, Adrian, Bodenheimer, Tom, Boice, Lori, Bootwalla, Moiz S., dos Reis, Rodolfo Borges, Boutros, Paul C., Bowen, Jay, Bowlby, Reanne, Boyd, Jeffrey, Breggia, Anne, Brimo, Fadi, Brooks, Denise, Broom, Bradley M., Bryce, Alan H., Bubley, Glenn, Burks, Eric, Butterfield, Yaron S.N., Button, Michael, Canes, David, Carlotti, Carlos G., Carlsen, Rebecca, Carroll, Peter R., Cartun, Richard, Carver, Brett S., Chan, June M., Chang, Matthew T., Chen, Yu, Costello, Anthony J., Cherniack, Andrew D., Chevalier, Simone, Cho, Juok, Chu, Andy, Chuah, Eric, Chudamani, Sudha, Ciriello, Giovanni, Clarke, Amanda, Cooperberg, Matthew R., Corcoran, Niall M., Cowan, Janet, Crain, Daniel, Curley, Erin, David, Kerstin, Demchok, John A., Demichelis, Francesca, Dhalla, Noreen, Dhir, Rajiv, Doueik, Alexandre, Drake, Bettina, Dvinge, Heidi, Dyakova, Natalya, Felau, Ina, Ferguson, Martin L., Frazer, Scott, Freedland, Stephen, Fu, Yao, Bristow, Christopher A., Gao, Jianjiong, Gardner, Johanna, Gastier-Foster, Julie M., Gehlenborg, Nils, Gerken, Mark, Gerstein, Mark B., Godwin, Andrew K., Gopalan, Anuradha, Graefen, Markus, Graim, Kiley, Gribbin, Thomas, Guin, Ranabir, Gupta, Manaswi, Hadjipanayis, Angela, Haider, Syed, Hamel, Lucie, Hayes, D. Neil, Hess, Julian, Hoadley, Katherine A., Holbrook, Andrea H., Holt, Robert A., Holway, Antonia, Hovens, Christopher M., Hoyle, Alan P., Huang, Mei, Hutter, Carolyn M., Ittmann, Michael, Iype, Lisa, Jefferys, Stuart R., Jones, Corbin D., Jones, Steven J.M., Juhl, Hartmut, Kahles, Andre, Kane, Christopher J., Kasaian, Katayoon, Kerger, Michael, Khurana, Ekta, Kim, Jaegil, Klein, Robert J., Kucherlapati, Raju, Lacombe, Louis, Ladanyi, Marc, Lai, Phillip H., Laird, Peter W., Latour, Mathieu, Lawrence, Michael S., Lau, Kevin, LeBien, Tucker, Lee, Darlene, Lee, Semin, Lehmann, Kjong-Van, Leraas, Kristen M., Leshchiner, Ignaty, Leung, Robert, Libertino, John A., Lichtenberg, Tara M., Linehan, W. Marston, Ling, Shiyun, Lippman, Scott M., Liu, Jia, Liu, Wenbin, Lochovsky, Lucas, Logothetis, Christopher, Lolla, Laxmi, Longacre, Teri, Lu, Yiling, Luo, Jianhua, Ma, Yussanne, Mahadeshwar, Harshad S., Mallery, David, Mariamidze, Armaz, Marra, Marco A., Mayo, Michael, McCall, Shannon, McKercher, Ginette, Meng, Shaowu, Mes-Masson, Anne-Marie, Merino, Maria J., Mieczkowski, Piotr A., Mills, Gordon B., Mills Shaw, Kenna R., Minner, Sarah, Moinzadeh, Alireza, Moore, Richard A., Morris, Scott, Morrison, Carl, Mose, Lisle E., Mungall, Andrew J., Murray, Bradley A., Myers, Jerome B., Naresh, Rashi, Nelson, Joel, Nelson, Mark A., Nelson, Peter S., Newton, Yulia, Noble, Michael S., Noushmehr, Houtan, Nykter, Matti, Pantazi, Angeliki, Parfenov, Michael, Parker, Joel S., Paulauskis, Joseph, Penny, Robert, Perou, Charles M., Piche, Alain, Pihl, Todd, Pinto, Peter A., Prandi, Davide, Protopopov, Alexei, Ramirez, Nilsa C., Rao, Arvind, Rathmell, W. Kimryn, Ratsch, Gunnar, Ren, Xiaojia, Reuter, Victor E., Reynolds, Sheila M., Rhie, Suhn K., Rieger-Christ, Kimberly, Roach, Jeffrey, Robertson, A. Gordon, Robinson, Brian, Rubin, Mark A., Saad, Fred, Sadeghi, Sara, Saksena, Gordon, Saller, Charles, Salner, Andrew, Sanchez-Vega, Francisco, Sander, Chris, Sandusky, George, Sauter, Guido, Sboner, Andrea, Scardino, Peter T., Scarlata, Eleonora, Schein, Jacqueline E., Schlomm, Thorsten, Schmidt, Laura S., Schultz, Nikolaus, Schumacher, Steven E., Neder, Luciano, Seth, Sahil, Sharp, Alexis, Shelton, Candace, Shelton, Troy, Shen, Hui, Shen, Ronglai, Sherman, Mark, Sheth, Margi, Shi, Yan, Shih, Juliann, Shmulevich, Ilya, Simko, Jeffry, Simon, Ronald, Simons, Janae V., Sipahimalani, Payal, Skelly, Tara, Sofia, Heidi J., Soloway, Matthew G., Song, Xingzhi, Sorcini, Andrea, Stepa, Serghei, Stewart, Chip, Stewart, John, Stuart, Joshua M., Sullivan, Travis B., Sun, Charlie, Sun, Huandong, Tam, Angela, Tan, Donghui, Tang, Jiabin, Tarnuzzer, Roy, Tarvin, Katherine, Taylor, Barry S., Teebagy, Patrick, Tenggara, Imelda, Tetu, Bernard, Tewari, Ashutosh, Thiessen, Nina, Thompson, Timothy, Thorne, Leigh B., Tirapelli, Daniela P., Tomlins, Scott A., Trevisan, Felipe Amstalden, Troncoso, Patricia, True, Lawrence D., Tsourlakis, Maria Christina, Tyekucheva, Svitlana, Van Allen, Eliezer, Van Den Berg, David J., Veluvolu, Umadevi, Vocke, Cathy D., Wan, Yunhu, Wang, Qingguo, Wang, Wenyi, Wang, Zhining, Weinhold, Nils, Weinstein, John N., Weisenberger, Daniel J., Wilkerson, Matthew D., Wise, Lisa, Witte, John, Wu, Chia-Chin, Wu, Junyuan, Wu, Ye, Xu, Andrew W., Yadav, Shalini S., Yang, Liming, Yang, Lixing, Yau, Christina, Ye, Huihui, Yena, Peggy, Zeng, Thomas, Zenklusen, Jean C., Zhang, Hailei, Zhang, Jiashan, Zhang, Wei, Zhong, Yi, Zhu, Kelsey, Zmuda, Erik, Cancer Genome Atlas Research Network, Bradley, Robert K., Meyerson, Matthew L., and Park, Peter J.

Abstract

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1 mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defects., National Institutes of Health (U.S.). (grant 5U24CA143799), National Institutes of Health (U.S.). (grant 5U24CA143835), National Institutes of Health (U.S.). (grant 5U24CA143840), National Institutes of Health (U.S.). (grant 5U24CA143843), National Institutes of Health (U.S.). (grant 5U24CA143845), National Institutes of Health (U.S.). (grant 5U24CA143848), National Institutes of Health (U.S.). (grant 5U24CA143858), National Institutes of Health (U.S.). (grant 5U24CA143866), National Institutes of Health (U.S.). (grant 5U24CA143867), National Institutes of Health (U.S.). (grant 5U24CA143882), National Institutes of Health (U.S.). (grant 5U24CA143883), National Institutes of Health (U.S.). (grant 5U24CA144025), National Institutes of Health (U.S.). (grant U54HG003067), National Institutes of Health (U.S.). (grant U54HG003079), National Institutes of Health (U.S.). (grant U54HG003273), National Institutes of Health (U.S.). (grant P30CA16672)

Published
2017

45. Reengineering the signaling properties of a Src family kinase

Author

Yadav, Shalini S., Yeh, Brian J., Craddock, Barbara P., Lim, Wendell A., and Miller, W. Todd

Subjects
Enzyme binding -- Analysis, Nitric oxide -- Chemical properties, Phosphotransferases -- Chemical properties, Tyrosine -- Chemical properties, Biological sciences, Chemistry
Abstract

The article discusses a new technique, which can be employed for the production of a new series of Src family kinases (SFKs), which are shown to exhibit completely different signaling properties. The various roles played by the different domains of the kinases are also explained.

Published
2009

46. The evolutionarily conserved arrangement of domains in Src family kinases is important for substrate recognition

Author

Yadav, Shalini S. and Miller, Todd W.

Subjects
Enzyme binding -- Analysis, Phosphorylation -- Analysis, Phosphotransferases -- Chemical properties, Phosphotransferases -- Genetic aspects, Biological sciences, Chemistry
Abstract

The substrate specificity of Src family kinases is investigated with the help of mutants. The positions of SH3 and SH2 domains are found to be significant in the enzyme regulation during phosphoryaltion.

Published
2008

47. Abstract 3772: A multi-scale survey to assess the impact of inflammatory diseases of the abdominal cavity and prostate cancer severity

Author

Shameer, Khader, primary, Yadav, Kamlesh Kumar, additional, Li, Li, additional, Yadav, Shalini S., additional, Glicksberg, Benjamin, additional, Khan, Irtaza, additional, Johnson, Kipp W., additional, Badgeley, Marcus A., additional, Elaiho, Cordelia, additional, Readhead, Ben, additional, Kidd, Brian A., additional, Kasarskis, Andrew, additional, Dudley, Joel T., additional, and Tewari, Ashutosh K., additional

Published
2017
Full Text
View/download PDF

48. Abstract 3250: Computational drug repositioning and biochemical validation of piperlongumine as a potent therapeutic agent for neuroendocrine prostate cancer

Author

Yadav, Kamlesh Kumar, primary, Shameer, Khader, additional, Readhead, Ben, additional, Stockert, Jennifer A., additional, Elaiho, Cordelia, additional, Yadav, Shalini S., additional, Glicksberg, Benjamin S., additional, Johnson, Kipp W., additional, Becker, Christine, additional, Kasarskis, Andrew, additional, Tewari, Ashutosh K., additional, and Dudley, Joel T., additional

Published
2017
Full Text
View/download PDF

50. MP14-08 A MULTISCALE SURVEY OF INFLAMMATORY DISEASES AND PROSTATE ONCOPHENOTYPES.

Author

Yadav, Kamlesh K, primary, Shameer, Khader, additional, Yadav, Shalini S, additional, Elaiho, Cordelia, additional, Li, Li, additional, O'Connor, James, additional, Glicksberg, Benjamin, additional, Jhonson, Kipp, additional, Badgeley, Marcus, additional, Readhead, Benjamin, additional, Kidd, Brian, additional, Kasarskis, Andrew, additional, Dudley, Joel, additional, and Tewari, Ashutosh, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results